Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,859
  • Shares Outstanding, K 68,907
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,820 K
  • 36-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.17
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.63 +6.35%
on 02/20/19
0.98 -31.28%
on 01/22/19
-0.28 (-29.47%)
since 01/18/19
3-Month
0.63 +6.35%
on 02/20/19
1.22 -45.08%
on 01/11/19
-0.24 (-26.37%)
since 11/20/18
52-Week
0.47 +42.55%
on 08/07/18
3.30 -79.70%
on 06/20/18
-1.35 (-66.83%)
since 02/20/18

Most Recent Stories

More News
Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares...

BLPH : 0.67 (-1.47%)
Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to market and other...

BLPH : 0.67 (-1.47%)
Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse(R) Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced top-line results from Cohort 1 of the Company's ongoing Phase 2b...

BLPH : 0.67 (-1.47%)
Bellerophon Therapeutics: 3Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Wednesday reported third-quarter net income of $11.1 million, after reporting a loss in the same period a year earlier.

BLPH : 0.67 (-1.47%)
Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter...

BLPH : 0.67 (-1.47%)
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from...

BLPH : 0.67 (-1.47%)
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter...

BLPH : 0.67 (-1.47%)
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with...

BLPH : 0.67 (-1.47%)
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

EXAS : 83.63 (-2.27%)
BLPH : 0.67 (-1.47%)
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

BLPH : 0.67 (-1.47%)
ALXN : 129.84 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLPH with:

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.70
Last Price 0.67
1st Support Level 0.63
2nd Support Level 0.60

See More

52-Week High 3.30
Fibonacci 61.8% 2.22
Fibonacci 50% 1.88
Fibonacci 38.2% 1.55
Last Price 0.67
52-Week Low 0.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar